恢复期血浆治疗预防和治疗COVID-19:事实和档案的系统研究,述评

K. Sridevi, Amit Munjal, A. Ch, S. Nachiappan, P. Raman, S. Bhalla, Sourya Kumar, A. Nayyar
{"title":"恢复期血浆治疗预防和治疗COVID-19:事实和档案的系统研究,述评","authors":"K. Sridevi, Amit Munjal, A. Ch, S. Nachiappan, P. Raman, S. Bhalla, Sourya Kumar, A. Nayyar","doi":"10.36648/2386-5180.8.2.314","DOIUrl":null,"url":null,"abstract":"Humanity has witnessed a pandemic in late December or, early January. Novel corona virus nCov-19 is responsible for causing COVID-19. The first case was reported in Wuhan city, China in the month of December 2019. No specific drugs have been approved yet for its treatment, though, convalescent plasma (CP) therapy is expected to increase the survivable rate. The history of convalescent plasma therapy dates back to the early 20th century. A plethora of studies suggest that CP can be used to treat the emerging infectious diseases. We had a systematic search in PubMed and found numerous Chinese and Korean clinical trials of convalescent plasma transfusions. The present review gives an insight in to the same.","PeriodicalId":8195,"journal":{"name":"Annals of Clinical and Laboratory Research","volume":"60 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":"{\"title\":\"Convalescent Plasma Therapy for Prophylaxis and Treatment of COVID-19: A Systematic Research of Facts and Files, A Narrative Review\",\"authors\":\"K. Sridevi, Amit Munjal, A. Ch, S. Nachiappan, P. Raman, S. Bhalla, Sourya Kumar, A. Nayyar\",\"doi\":\"10.36648/2386-5180.8.2.314\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Humanity has witnessed a pandemic in late December or, early January. Novel corona virus nCov-19 is responsible for causing COVID-19. The first case was reported in Wuhan city, China in the month of December 2019. No specific drugs have been approved yet for its treatment, though, convalescent plasma (CP) therapy is expected to increase the survivable rate. The history of convalescent plasma therapy dates back to the early 20th century. A plethora of studies suggest that CP can be used to treat the emerging infectious diseases. We had a systematic search in PubMed and found numerous Chinese and Korean clinical trials of convalescent plasma transfusions. The present review gives an insight in to the same.\",\"PeriodicalId\":8195,\"journal\":{\"name\":\"Annals of Clinical and Laboratory Research\",\"volume\":\"60 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Clinical and Laboratory Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36648/2386-5180.8.2.314\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical and Laboratory Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36648/2386-5180.8.2.314","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

摘要

人类在12月底或1月初目睹了一场大流行。新型冠状病毒nCov-19是导致COVID-19的原因。首例病例于2019年12月在中国武汉市报告。目前还没有专门的药物被批准用于治疗这种疾病,但恢复期血浆(CP)疗法有望提高生存率。恢复期血浆治疗的历史可以追溯到20世纪初。大量研究表明,CP可用于治疗新发传染病。我们在PubMed进行了系统的搜索,发现了许多中国和韩国的恢复期血浆输注的临床试验。目前的审查提供了一个相同的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Convalescent Plasma Therapy for Prophylaxis and Treatment of COVID-19: A Systematic Research of Facts and Files, A Narrative Review
Humanity has witnessed a pandemic in late December or, early January. Novel corona virus nCov-19 is responsible for causing COVID-19. The first case was reported in Wuhan city, China in the month of December 2019. No specific drugs have been approved yet for its treatment, though, convalescent plasma (CP) therapy is expected to increase the survivable rate. The history of convalescent plasma therapy dates back to the early 20th century. A plethora of studies suggest that CP can be used to treat the emerging infectious diseases. We had a systematic search in PubMed and found numerous Chinese and Korean clinical trials of convalescent plasma transfusions. The present review gives an insight in to the same.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Research and Recent Advancements on Multiple Sclerosis Emerging Public Health Threats and their Health Perspectives Immunology and Multiple Sclerosis Risk with Air Pollution Seroprevalence of Cytomegalovirus among Schizophrenic Patients in Khartoum State Short Communication on Anesthesiology
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1